Cat Vaccine Market Report 2026

Cat Vaccine Market Overview

• Cat Vaccine market size has reached to $1.26 billion in 2025 • Expected to grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Zoonotic Diseases Fuel The Growth Of The Cat Vaccine Market • Market Trend: Innovations In Cat Vaccines NOBIVAC NXT Utilizes RNA-Particle Technology For Enhanced Feline Disease Protection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cat Vaccine Market?

A cat vaccine is a biological preparation designed to protect cats from infectious diseases by stimulating their immune system to recognize and fight off specific pathogens. These vaccines contain weakened or inactivated forms of viruses or bacteria that cause diseases, prompting the cat's immune system to produce antibodies without causing illness. The main types of cat vaccines are modified or attenuated live, inactivated, and others. Modified or attenuated live vaccines are created by weakening the pathogen that causes disease so it cannot cause illness in cats. The various disease types include feline leukemia, feline panleukopenia, feline respiratory diseases, feline rabies, and others. The various technologies include attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, deoxyribonucleic acid (DNA) vaccines, recombinant vaccines with various routes of administration that include injectables, intranasal, and oral. These are distributed by various distribution channels such as veterinary clinics, pet stores, and online retailers.

What Is The Cat Vaccine Market Growth Forecast?

The cat vaccine market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to technological advancements in vaccine development, increasing demand for recombinant and dna vaccines, rising awareness of preventive healthcare in pets, expansion of online veterinary services, integration of ai and data analytics in disease monitoring. Major trends in the forecast period include increased adoption of core vaccination programs, growth of recombinant and dna vaccines, expansion of veterinary healthcare services, rising awareness of pet health and disease prevention, integration of telemedicine and remote monitoring in veterinary care.

What Is The Driver Of The Cat Vaccine Market?

The increasing prevalence of zoonotic diseases is expected to propel the growth of the cat vaccine market going forward. Zoonotic diseases are infections that can pass from animals to humans, caused by pathogens such as bacteria, viruses, fungi, or parasites. These diseases can spread through direct contact, vectors, or contaminated environments. The common zoonotic diseases are lyme disease, rabies, toxoplasmosis, salmonellosis, brucellosis, and more. The increasing prevalence of zoonotic diseases is due to climate change, antibiotic resistance, and illegal and legal wildlife trade. Cat vaccines control zoonotic diseases by reducing the risk of transmission from cats to humans by vaccinating cats against diseases such as toxoplasmosis and cat scratch fever. This proactive approach helps mitigate zoonotic diseases' impact on human health, supports public health efforts, and ensures a healthier environment for pets and their owners. For instance, in February 2024, according to a report published by the Government of the United Kingdom, a UK-based government agency, in the fourth quarter of 2023, England reported 335 confirmed cases of Lyme disease, an increase from the 273 cases recorded during the same period in 2022. Therefore, the increasing zoonotic diseases drive the cat vaccine industry.

Key Players In The Global Cat Vaccine Market

Major companies operating in the cat vaccine market are Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Virbac, HIPRA Corporation, Bioveta AS, Biogénesis Bagó SA, Torigen Pharmaceuticals Inc., Vetoquinol SA, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova BV, Colorado Serum Company, Huvepharma NV, Bimeda Biologicals, CAVAC, Kyoto Biken Laboratories, Avimex Animal Health, Ringpu Biology, Wuhan Keqian Biology, Pulike Biological Engineering, Chengdu Kanghua Biological Products, Yebio, FATRO

Global Cat Vaccine Market Trends and Insights

Major companies operating in the cat vaccine market are focused on developing innovative products such as NOBIVAC NXT vaccines that utilize state-of-the-art Ribonucleic acid (RNA)-particle technology to enhance immune responses, improve vaccine efficacy, and provide targeted protection against feline diseases. State-of-the-art Ribonucleic acid (RNA)-particle technology is an innovative approach that uses RNA molecules encapsulated in nanoparticles to deliver genetic instructions to cells, prompting them to produce specific proteins that stimulate a targeted immune response. For instance, in June 2024, MSD Animal Health Inc., a US-based pharmaceutical company, launched The NOBIVAC NXT Rabies portfolio consists of NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies, a comprehensive vaccination solution designed to provide effective protection against rabies in cats and dogs. The NOBIVAC NXT vaccines are formulated without adjuvants and preservatives, enhancing their safety profile while maintaining efficacy. The vaccines stimulate both humoral (antibody-mediated) and cell-mediated immune responses, providing comprehensive protection against the rabies virus.

What Are Latest Mergers And Acquisitions In The Cat Vaccine Market?

In September 2024, Boehringer Ingelheim Group, a Germany-based pharmaceutical company, acquired Saiba Animal Health AG for an undisclosed amount. This acquisition marked Boehringer Ingelheim's strategic move to expand its portfolio by incorporating Saiba's expertise in providing cat vaccines. Saiba Animal Health AG is a Switzerland-based company that offers cat vaccines.

What Defines the Cat Vaccine Market?

The cat vaccine market consists of sales of the bordetella vaccine, rabies vaccine, and feline immunodeficiency virus (FIV) vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cat Vaccine Market Report 2026?

The cat vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cat vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.